Page 46 - Q1 Results

Birla Corporation Q1 results: Net profit declines 45% to Rs 33 cr

M P Birla group flagship firm Birla Corporation on Thursday posted a 45 per cent decline in its net profit to Rs 33 crore during the first quarter of the 2024-25 fiscal as compared to Rs 60 crore in the year-ago period. A company statement said that revenue of the company during the April-June period also decreased by 8.9 per cent at Rs 2,207 crore as against Rs 2,423 crore in the similar previous quarter It said weak cement prices coupled with sluggish demand have weighed down the profitability of the June quarter. Sales volumes also declined marginally in the face of contracting demand. Faced with challenging market conditions, the Kolkata-headquartered company focused on reducing variable costs in cement production across its units. The jute division of the company registered a cash loss of Rs 3.9 crore in the quarter under review against a cash profit of Rs 6.4 crore in the similar previous period. Realisation of cement sales per tonne during the first three months of the curr

JB Pharma Q1 FY25 results: Net profit rises 24% to Rs 176.83 crore

Company crosses Rs 1,000 crore quarterly revenue mark

AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr

AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024. The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal. Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing. "We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said. Shares of AstraZeneca Pharma on Thursday ended 6.77 per cent lower at Rs 6,613.40 apiece on the BSE.

Oil India Q1 results: PAT declines 9% to Rs 1,467 cr on higher expenses

Its profit fell 9 per cent year-on-year to Rs 1,467 crore (about $175 million) in the three months ended June 30, falling behind analysts' predicted profit of Rs 1,687 crore, per LSEG data

JB Chemicals & Pharma Q1 results: Net profit jumps 25% to Rs 177 cr

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .

LIC Q1 results: PAT up 10% at Rs 10,461 cr, total income at Rs 2.1 trn

Life Insurance Corporation of India (LIC) on Thursday reported a 10 rise in its net profit to Rs 10,461 crore in the June 2024 quarter. The state-owned life insurance behemoth had a net profit of Rs 9,544 crore in the year-ago period. The total income increased to Rs 2,10,910 crore during the latest June quarter as against Rs 1,88,749 crore in the year-ago period, LIC said in a regulatory filing. During the quarter under review, the first-year premium rose to Rs 7,470 crore as against Rs 6,811 crore in the year-ago period, it said. The insurer earned Rs 56,429 crore from renewal premiums as against Rs 53,638 crore a year ago. Net income from investments during the quarter rose to Rs 96,183 crore as compared to Rs 90,309 crore in the April-June period of previous fiscal. Solvency margin of LIC increased to 1.99 per cent as compared to 1.89 per cent in the same quarter a year ago.

Sobha Ltd Q1 results: Net profit sinks 50% to Rs 6.06 cr on lower sales

The April-June period saw delays in approvals for real estate projects amidst general elections in the country, resulting in fewer launches and a slowdown in sales

Eicher Motors Q1 results: Profit rises 20% to Rs 1,101 cr on strong sales

Eicher clocked record-high sales in the previous two fiscal years due to strong demand from urban consumers, its key demographic

Ajmera Realty & Infra India Q1 results: PAT jumps 49% to Rs 31.43 cr

Ajmera Realty & Infra India on Thursday reported a 49 per cent increase in its consolidated net profit to Rs 31.43 crore for the quarter ending June. Its profit stood at Rs 21.07 crore in the year-ago period. Total income rose to Rs 196.15 crore in the April-June period of this fiscal from Rs 117.57 crore in the corresponding period of the previous year, according to a regulatory filing. Dhaval Ajmera, Director of Ajmera Realty & Infra India, said the company continued its robust growth momentum with a stellar performance across all financial metrics, driven by strong sales growth and excellent collection efficiencies across all projects. This growth trajectory is a testament to the company's coveted launch pipeline and paves the way further towards full-year guidance, he said.

Page Industries Q1 results: Net profit rises to Rs 165 cr on strong demand

The apparel maker reported a profit of Rs 165 crore(nearly $20 million) for the quarter ended June 30, compared with Rs 158 crore a year ago

Airtel Payments Bank Q1 results: PAT up 41% to Rs 7.2 cr on revenue rise

Airtel Payments Bank on Thursday said its net profit for the June quarter rose 41 per cent year-on-year to Rs 7.2 crore, amid uptick in digital savings bank accounts alongside other digital offerings. Announcing its consolidated report card for the first quarter ended on June 30, 2024, Airtel Payments Bank said it has hit a significant milestone and that, in a first, the bank's quarterly revenue grew to Rs 610 crore, up by 52 per cent on-year. The net profits stood at Rs 7.2 crore, up by 41 per cent year on year. "During the quarter, the Bank's Monthly Transacting Users (MTU) exceeded 88 million giving a boost to customer deposits, which grew by 53 per cent year-on-year to Rs 2,943 crore," it said. The Bank's annualised gross merchandise value stands at over Rs 3,400 billion (Rs 3,40,000 crore). "The growth in revenue and MTUs has been driven primarily by an uptake in the Bank's digital savings bank account along with other digital offerings. The Bank's eco-friendly NCMC (National

RVNL Q1 results: Net profit falls 35% to Rs 224 cr on reduced income

State-owned Rail Vikas Nigam Ltd (RVNL) on Thursday posted around 35 per cent fall in consolidated net profit to Rs 223.92 crore during the June quarter of FY25, mainly on account of reduced income. It had reported a net profit of Rs 343.09 crore during the April-June period of the preceding 2023-24 fiscal, the company said in an exchange filing. The company's total income decreased to Rs 4,336.75 crore from Rs 5,853.18 crore in the year-ago quarter. RVNL, under the Ministry of Railways, is involved in project development, financing and implementation of projects related to rail infrastructure.

Alembic Pharma Q1FY25 results: Net profit increases 12% to Rs 135 cr

Alembic Pharmaceuticals on Thursday said its consolidated net profit increased by 12 per cent to Rs 135 crore for the first quarter ended on June 30, 2024. The drug firm had reported a net profit of Rs 121 crore for the April-June quarter of last fiscal. Total income increased to Rs 1,564 crore for the June quarter as against Rs 1,498 crore in the year-ago period, Alembic Pharmaceuticals said in a regulatory filing. "India branded business continues to work on improving the execution ability both in quality and scale," Alembic Pharmaceuticals MD Shaunak Amin said. The specialty and animal health segment witnessed robust growth, he added. "The USFDA conducted an audit at our formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18 per cent during the quarter," Amin said. Shares of the company ended 0.11 per cent down at Rs 1,218.65 apiece on the BSE.

MRF Q1 results: Net profit dips to Rs 571 cr, total income at Rs 7,280 cr

Tyre maker MRF on Thursday said its consolidated net profit declined by 3 per cent year-on-year to Rs 571 crore for the first quarter ended June 30, 2024. The company had reported a net profit of Rs 589 crore in the April-June quarter of last fiscal. Total income increased to Rs 7,280 crore for the period under review as against Rs 6,515 crore in the June quarter of FY24, MRF Ltd said in a regulatory filing. Shares of the company were trading 4.80 per cent higher at Rs 1,41,130 apiece on the BSE.

Brookfield India REIT Q1 results: PAT jumps to Rs 37.3 cr, NOI at Rs 440 cr

Brookfield India Real Estate Trust has reported a 93 per cent jump in its net operating income to Rs 439.9 crore and declared a distribution of Rs 216 crore for the June 2024 quarter. Its net operating income (NOI) stood at Rs 227.5 crore in the year-ago period. According to a regulatory filing on Wednesday, Brookfield India Real Estate Trust declared a distribution of Rs 216 crore or Rs 4.50 per unit for the quarter ended June 30, 2024. The company's net profit stood at Rs 37.35 crore in the first quarter of this fiscal against a loss of Rs 27 crore in the year-ago period. Total income rose to Rs 590.91 crore from Rs 320.73 crore during the period under review. Brookfield India Real Estate Trust achieved gross leasing of 2,42,000 square feet at Rs 135 per square feet. During the June quarter, the company informed that it has completed the acquisition of a 50 per cent stake in a 3.3 million square feet commercial portfolio in Delhi-NCR from Bharti Enterprises for Rs 1228 ...

Lupin stock soars: Analysts bullish on growth but valuation may cap upside

Brokerages sang in unison about Lupin's growth outlook but stayed divided on the valuation front with many calling the current trading values - a bit expensive

BSE stock jumps 11% post robust June quarter earnings; check details here

Shares of Bombay Stock Exchange (BSE) rose 10.77 per cent, at Rs 2,940 per share on the NSE in Thursday's intraday deals

Shree Cement extends fall; stock down 13% in 6 days post weak Q1 results

Management indicated that cement demand would remain weak until calendar year 2024-end and expects a full recovery from Q4FY25, brokerage firm MOFSL said.

These companies reported turnaround in Q1; what lies ahead for stocks?

Zee Entertainment, PB Fintech, Delhivery among select companies to report a turnaround in the June 2024 quarter. Here's a technical outlook on select such stocks.

Delhivery expects to drive on with seasonal uptick, new business growth

Most brokerages are positive about logistics company, expect it to sustain profits